# Omniscient Neurotechnology (o8t)

> Omniscient Neurotechnology (o8t) is a Sydney-based brain-mapping company that uses AI and machine learning to turn ordinary MRI scans into detailed maps of the brain's electrical networks, or connectomes. Its flagship FDA-cleared platform, Quicktome, gives neurosurgeons a patient-specific view of the pathways responsible for speech, movement and cognition before they operate, while its research platform, Infinitome, helps scientists study how diseases like Alzheimer's, epilepsy and schizophrenia disrupt brain connectivity. Founded in 2019 and led by CEO Stephen Scheeler, the company has raised roughly US$124 million to date and is expanding connectomics into stroke, movement disorders and brain-computer interfaces.

- **Founded:** 2019
- **Headquarters:** Sydney, Australia
- **Founders:** Michael Sughrue (Co-Founder & Chief Medical Officer), Stephane Doyen (Co-Founder & Chief Data Scientist / CTO)
- **Team size:** ~65 employees
- **Products:** Quicktome, Quicktome FC (Functional Connectome), Infinitome
- **Notable:** Launched Quicktome, described as among the first FDA-cleared medical devices to bring connectomics into routine neurosurgical planning (2021)., Secured FDA 510(k) clearance plus Health Canada and Australian TGA approvals for Quicktome., Added FDA clearance for Quicktome FC functional connectome analysis (2023).

## Products & services

- **Quicktome** — FDA-cleared clinical brain-mapping platform that generates patient-specific connectomic maps from MRI, giving neurosurgeons a view of functional regions and neural pathways (speech, movement, cognition) to inform surgical planning. Cleared in the US, Canada and Australia.
- **Quicktome FC (Functional Connectome)** — FDA-cleared functional brain-analysis release that reveals an individual's unique connectivity patterns from a single MRI scan.
- **Infinitome** — Cloud-based research platform for analyzing brain networks at scale, used to study how diseases such as Alzheimer's, epilepsy, schizophrenia and multiple sclerosis disrupt the brain's electrical connections and to identify potential biomarkers.

## Achievements

- Launched Quicktome, described as among the first FDA-cleared medical devices to bring connectomics into routine neurosurgical planning (2021).
- Secured FDA 510(k) clearance plus Health Canada and Australian TGA approvals for Quicktome.
- Added FDA clearance for Quicktome FC functional connectome analysis (2023).
- Raised roughly US$124M in total funding across Series B, C and D rounds.
- Obtained a US CPT code (1039T) creating a reimbursement pathway for connectomic analysis.
- Attracted repeat backing from Gina Rinehart and Will Vicars, plus government co-investment via NRFC.

## Latest updates

- **2026-05** — Raised US$27.2M oversubscribed Series D co-led by OIF Ventures and the NRFC to accelerate commercialization and expand into stroke, movement disorders and brain-computer interfaces.
- **2024-06** — Closed a Series C funding round (reported ~US$89M) backed by Gina Rinehart and Will Vicars.
- **2023-06** — Announced FDA clearance of Quicktome FC, an MRI-based functional brain-analysis technology.

## Links

- Website: https://o8t.com
- LinkedIn: https://www.linkedin.com/company/omniscientneurotechnology
- Twitter/X: https://twitter.com/o8tneuro

---

Profile page: https://yespress.io/omniscient-neurotechnology-o8t
Published by YesPress — https://yespress.io
Last updated: 2026-07-25